We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

February 13, 2018

Kim v. Cascadian Therapeutics, Inc. et al

Track this case

Case Number:




Nature of Suit:

Stockholders Suits

Multi Party Litigation:

Class Action


Gregory M. Sleet


View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


  1. February 14, 2018

    Cascadian Investor Says $614M Deal Statement Omitted Info

    A shareholder of biopharmaceutical company Cascadian Therapeutics Inc. launched a class action on Tuesday in Delaware federal court alleging the company’s directors omitted material information from documents detailing a proposed $614 million merger deal with Seattle Genetics Inc.


To view the parties, register now.